Daiichinkyo Co (FRA:D4S) ROCE %

: 18.33% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Daiichinkyo Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 18.33%.

Daiichinkyo Co ROCE % Historical Data

The historical data trend for Daiichinkyo Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

5.76

8.85

4.22

4.44

6.80

Daiichinkyo Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															7.77	-0.19	10.11	10.54	18.33

Daiichinkyo Co ROCE % Calculation

Daiichinkyo Co's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	945.667	/	( ( (17010.265 - 3026.743)	+	(17531.25 - 3705.295) )	/ 2 )
	=	945.667	/	( (13983.522	+	13825.955)	/ 2 )
	=	945.667	/	13904.7385
	=	6.80 %

Daiichinkyo Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	2783.376	/	( ( (16789.257 - 3373.263)	+	(20819.498 - 3864.709) )	/ 2 )
	=	2783.376	/	( ( 13415.994	+	16954.789 )	/ 2 )
	=	2783.376	/	15185.3915
	=	18.33 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Daiichinkyo Co (FRA:D4S) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Daiichinkyo Co ROCE % Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (FRA:D4S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (FRA:D4S) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA 4568:Japan D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (FRA:D4S) Headlines

No Headlines